Home Cart 0 Sign in  
X

[ CAS No. 35150-07-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 35150-07-3
Chemical Structure| 35150-07-3
Chemical Structure| 35150-07-3
Structure of 35150-07-3 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 35150-07-3 ]

Related Doc. of [ 35150-07-3 ]

Alternatived Products of [ 35150-07-3 ]
Product Citations

Product Details of [ 35150-07-3 ]

CAS No. :35150-07-3 MDL No. :MFCD00190827
Formula : C10H18N2O3 Boiling Point : -
Linear Structure Formula :- InChI Key :-
M.W : 214.26 Pubchem ID :-
Synonyms :

Calculated chemistry of [ 35150-07-3 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 15
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.8
Num. rotatable bonds : 4
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 59.5
TPSA : 72.63 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.57 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.9
Log Po/w (XLOGP3) : 0.05
Log Po/w (WLOGP) : 0.49
Log Po/w (MLOGP) : 0.33
Log Po/w (SILICOS-IT) : -0.02
Consensus Log Po/w : 0.55

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -0.94
Solubility : 24.8 mg/ml ; 0.116 mol/l
Class : Very soluble
Log S (Ali) : -1.13
Solubility : 15.9 mg/ml ; 0.0744 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -0.59
Solubility : 54.8 mg/ml ; 0.256 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.58

Safety of [ 35150-07-3 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 35150-07-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 35150-07-3 ]
  • Downstream synthetic route of [ 35150-07-3 ]

[ 35150-07-3 ] Synthesis Path-Upstream   1~21

  • 1
  • [ 15761-39-4 ]
  • [ 35150-07-3 ]
YieldReaction ConditionsOperation in experiment
85% With pyridine; ammonium bicarbonate In 1,4-dioxane at 20℃; for 6 h; General procedure: A mixture of compound 1 (1.00 g, 4.65 mmol), (Boc)2O (1.52 g, 6.97 mmol), NH4HCO3 (0.55 g, 6.97 mmol) and pyridine (1.0 mL) in dioxane (20 mL) was stirred at room temperature for 6 h. the product was extracted with CH2Cl2, washed with 1 M HCl and saturated NaCl, dried, filtrated, and concentrated. n-Hexane (100 mL) was added and the product 2 (0.85 g, 85percent) began to precipitate using the ultrasound as a white solid. 1H NMR (300 MHz, CDCl3) δ 4.37–4.34 (m, 1H), 3.47–3.36 (m, 2H), 2.07–1.85 (m, 4H), 1.49 (s, 9H). MS (ESI) m/z 215 [M+H]+.
85% With pyridine; di-<i>tert</i>-butyl dicarbonate; ammonium bicarbonate In 1,4-dioxane at 20℃; for 6 h; A mixture of compound 8 (1.00 g, 4.65 mmol), (Boc)2O (1.52 g, 6.97 mmol), NH4HCO3 (0.55 g, 6.97 mmol) and pyridine (1.0 mL) indioxane (20 mL) was stirred at room temperature for 6 h. the product wasextracted with CH2Cl2, washed with 1M HCl and saturated NaCl, dried, filtrated,and concentrated. n-hexane (100 mL) was added and the product 9 (0.85 g, 85percent) began to precipitate using the ultrasoundas a white solid . 1H NMR (CDCl3, 300 MHz):δ4.37-4.34(m, 1H), 3.47-3.36 (m, 2H), 2.07-1.85 (m, 4H), 1.49 (s, 9H). MS (ESI) m/z 215[M+H]+.
76%
Stage #1: With 4-methyl-morpholine; isobutyl chloroformate In tetrahydrofuran at 0℃; for 0.583333 h;
Stage #2: With ammonium hydroxide In tetrahydrofuran at 0 - 20℃; for 4 h;
General procedure: The solution of Boc-L-proline 1 g, 4.6 mmol,) in THF (12 mL) at 0 °C was charged with N-Methylmorpholine (0.54 g, 5.38 mmol). Then isobutyl chloroformate (0.75 g, 5.52 mmol) was added dropwise over 5 minutes. After 30 minutes of stirring the reaction was treated with the 25percent aqueous solution of ammonia (0.53 g, 15.18 mmol). The mixture was allowed to warm to room temperature and stirred for 4 h. Then, the mixture was concentrated under reduced pressure. Product was crystallized from hexane to yield 0.76 g (76percent) of product 1 as colorless crystals.
Reference: [1] Bioorganic and Medicinal Chemistry, 2002, vol. 10, # 6, p. 1719 - 1729
[2] Canadian Journal of Chemistry, 2007, vol. 85, # 2, p. 85 - 95
[3] Journal of Agricultural and Food Chemistry, 2012, vol. 60, # 35, p. 8544 - 8551
[4] Journal of Medicinal Chemistry, 2017, vol. 60, # 1, p. 228 - 247
[5] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 23, p. 7418 - 7429
[6] European Journal of Medicinal Chemistry, 2014, vol. 75, p. 111 - 122
[7] Tetrahedron Letters, 1995, vol. 36, # 39, p. 7115 - 7118
[8] Tetrahedron, 2008, vol. 64, # 12, p. 2801 - 2815
[9] Bulletin of the Chemical Society of Japan, 1988, vol. 61, # 7, p. 2647 - 2648
[10] European Journal of Medicinal Chemistry, 2015, vol. 92, p. 202 - 211
[11] Tetrahedron, 2009, vol. 65, # 46, p. 9536 - 9541
[12] Polish Journal of Chemistry, 1986, vol. 60, # 1-3, p. 95 - 105
[13] Tetrahedron Letters, 1991, vol. 32, # 39, p. 5359 - 5362
[14] Synthetic Communications, 2009, vol. 39, # 3, p. 395 - 406
[15] Patent: US2011/136799, 2011, A1, . Location in patent: Page/Page column 43
[16] Journal of Medicinal Chemistry, 2011, vol. 54, # 10, p. 3524 - 3548
[17] Journal of Antibiotics, 2013, vol. 66, # 5, p. 259 - 264
[18] Chemical Biology and Drug Design, 2015, vol. 85, # 4, p. 439 - 446
[19] Angewandte Chemie - International Edition, 2016, vol. 55, # 27, p. 7698 - 7701[20] Angew. Chem., 2016, vol. 128, p. 7829 - 7832,4
[21] Journal of the American Chemical Society, 2017, vol. 139, # 48, p. 17500 - 17507
  • 2
  • [ 24424-99-5 ]
  • [ 7531-52-4 ]
  • [ 35150-07-3 ]
Reference: [1] Tetrahedron Letters, 2011, vol. 52, # 42, p. 5435 - 5437
[2] Patent: WO2011/101861, 2011, A1, . Location in patent: Page/Page column 18
[3] Patent: WO2014/20462, 2014, A1, . Location in patent: Page/Page column 9
[4] Patent: CN107033054, 2017, A, . Location in patent: Paragraph 0070; 0071; 0073; 0074; 0111; 0113; 0114
  • 3
  • [ 15761-39-4 ]
  • [ 35150-07-3 ]
YieldReaction ConditionsOperation in experiment
43%
Stage #1: With benzotriazol-1-ol; 1,2-dichloro-ethane In tetrahydrofuran at 20℃; for 6 h;
71f[0529] (S)-tert-butyl 2-carbamoylpyrrolidine-1-carboxylate (71a): To a solution of 1-(tert- butoxycarbonyl)pyrrolidine-2-carboxylic acid (0.2 g, 0.93 mmol) in THE (13 mL), HOBT (142 mg, 0.93 mmol) was added followed by EDC (205 mg, 1.07 mmol). After stirring at r.t. for 6 hours, concentrated ammonium hydroxide (0.3 mL, 6.50 mmol) was added and the reaction mixture was stirred for 16-60 hours. Once reaction showed by TLC to be at completion, the organic solvent was removed under reduced pressure and the residue was diluted with ethyl acetate. The organic layer was washed with sodium bicarbonate solution and brine, dried over sodium sulfate, and concentrated to afford final product 71a (87 mg, 43percent) as an oil. 1H NMR (500 MHz, CDCI3) 64.17 (d, i=62.9 Hz, 1H), 3.35 (d, i=67.9 Hz, 2H), 2.26-1.98 (m, 2H), 1.92-1.75 (m, 2H), 1.39 (s, 9H); 13C NMR (126 MHz, CDCI3) 6175.15, 154.61, 80.33, 59.67, 47.15, 31.12, 28.37, 24.52. HRMS (ESI+): Calcd for C10H19N203 [M+H]: 215.1395, Eound:215.1389.
Reference: [1] Patent: WO2013/119946, 2013, A1, . Location in patent: Paragraph 0529
  • 4
  • [ 135339-65-0 ]
  • [ 35150-07-3 ]
Reference: [1] Tetrahedron Letters, 1998, vol. 39, # 27, p. 4869 - 4870
  • 5
  • [ 59936-29-7 ]
  • [ 35150-07-3 ]
Reference: [1] Journal of Medicinal Chemistry, 2009, vol. 52, # 21, p. 6672 - 6684
  • 6
  • [ 137862-19-2 ]
  • [ 35150-07-3 ]
Reference: [1] Tetrahedron Letters, 1991, vol. 32, # 39, p. 5359 - 5362
  • 7
  • [ 24424-99-5 ]
  • [ 35150-07-3 ]
Reference: [1] Journal of Medicinal Chemistry, 2011, vol. 54, # 10, p. 3524 - 3548
[2] Journal of Medicinal Chemistry, 2011, vol. 54, # 10, p. 3524 - 3548
[3] Journal of Agricultural and Food Chemistry, 2012, vol. 60, # 35, p. 8544 - 8551
[4] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 23, p. 7418 - 7429
[5] European Journal of Medicinal Chemistry, 2014, vol. 75, p. 111 - 122
  • 8
  • [ 147-85-3 ]
  • [ 35150-07-3 ]
Reference: [1] Journal of Medicinal Chemistry, 2011, vol. 54, # 10, p. 3524 - 3548
[2] Journal of Agricultural and Food Chemistry, 2012, vol. 60, # 35, p. 8544 - 8551
[3] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 23, p. 7418 - 7429
[4] European Journal of Medicinal Chemistry, 2014, vol. 75, p. 111 - 122
  • 9
  • [ 28310-65-8 ]
  • [ 35150-07-3 ]
Reference: [1] Polish Journal of Chemistry, 1986, vol. 60, # 1-3, p. 95 - 105
  • 10
  • [ 3392-10-7 ]
  • [ 35150-07-3 ]
Reference: [1] Synthetic Communications, 1994, vol. 24, # 9, p. 1239 - 1246
  • 11
  • [ 37784-17-1 ]
  • [ 35150-07-3 ]
Reference: [1] Journal of Medicinal Chemistry, 2011, vol. 54, # 10, p. 3524 - 3548
  • 12
  • [ 15761-39-4 ]
  • [ 35150-07-3 ]
  • [ 70138-72-6 ]
Reference: [1] Advanced Synthesis and Catalysis, 2012, vol. 354, # 13, p. 2531 - 2536
  • 13
  • [ 24424-99-5 ]
  • [ 147-85-3 ]
  • [ 35150-07-3 ]
Reference: [1] Chemical Biology and Drug Design, 2015, vol. 85, # 4, p. 439 - 446
[2] Angewandte Chemie - International Edition, 2016, vol. 55, # 27, p. 7698 - 7701[3] Angew. Chem., 2016, vol. 128, p. 7829 - 7832,4
[4] Journal of the American Chemical Society, 2017, vol. 139, # 48, p. 17500 - 17507
  • 14
  • [ 15761-39-4 ]
  • [ 24424-99-5 ]
  • [ 35150-07-3 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 23, p. 5257 - 5261
  • 15
  • [ 84890-94-8 ]
  • [ 35150-07-3 ]
Reference: [1] Polish Journal of Chemistry, 1986, vol. 60, # 1-3, p. 95 - 105
  • 16
  • [ 344-25-2 ]
  • [ 35150-07-3 ]
Reference: [1] Journal of Medicinal Chemistry, 2011, vol. 54, # 10, p. 3524 - 3548
  • 17
  • [ 15761-39-4 ]
  • [ 35150-07-3 ]
  • [ 70138-72-6 ]
Reference: [1] Advanced Synthesis and Catalysis, 2012, vol. 354, # 13, p. 2531 - 2536
  • 18
  • [ 35150-07-3 ]
  • [ 228244-04-0 ]
YieldReaction ConditionsOperation in experiment
76% With 1,3,5-trichloro-2,4,6-triazine In N,N-dimethyl-formamide at 20℃; for 1 h; General procedure: A mixture of compound 2 (5 g, 23.3 mmol) and cyanuric chiloride (2.58 g, 14.0 mmol) in DMF (10 mL) was stirred at room temperature for 1 h (monitored by TLC). After the reaction completed, the solution was extracted with EtOAc, washed, dried, concentrated, and purified by flash chromatography on silica gel, eluted with a mixture of PE/EA (1/1, v/v), to afford 3 (3.48 g, 76percent) as a white solid. 1H NMR (300 MHz, CDCl3) δ 4.76 (s, 1H), 3.51 (s, 2H), 2.34-2.31 (m, 1H), 2.17-2.10 (m, 2H), 1.90–1.87 (m, 1H), 1.49 (s, 9H). MS (ESI) m/z 197 [M+H]+.
76% With 1,3,5-trichloro-2,4,6-triazine In N,N-dimethyl-formamide at 20℃; for 1 h; A mixture of compound 9 (5 g, 23.3 mmol) and cyanuric chiloride (2.58 g, 14.0 mmol) in DMF (10 mL) was stirred at roomtemperature for 1 h (monitored by TLC). After the reaction completed, thesolution was extracted with EtOAc, washed, dried, concentrated, and purified byflash chromatography on silica gel, eluted with a mixture of PE/EA (1/1, v/v)to afford 10 (3.48 g, 76percent) as a white solid. 1H NMR (CDCl3,300 MHz): δ4.76(s, 1H), 3.51 (s, 2H), 2.34-2.31 (m, 1H), 2.17-2.10 (m, 2H), 1.90-1.87 (m, 1H),1.49 (s, 9H). MS (ESI) m/z 197[M+H]+.
55 g With triethylamine; trifluoroacetic anhydride In dichloromethane at -15℃; for 3 h; step 1:The first reaction solution containing the compound represented by Formula II was cooled to -15.0 ° C., 30.0 g of triethylamine,A dichloromethane solution containing 0.357 mol of trifluoroacetic anhydride (TFAA) was added dropwise,Dropping time 2h, after the addition was completed, incubated for 1h,Insulation temperature was -15.0 , TLC monitoring showed that the reaction was completed;Step 2: To the solution in Step 1 was added purified water 100mL, washed and stratified;The pH was adjusted to 1 with 1 M hydrochloric acid, the temperature was controlled below 0 ° C,Stirring for 30-45min, standing stratification;Step 3: The mass concentration of 5percent -10percent dilute salt water 100mL wash phase;The organic layer was dried over sodium sulfate, filtered and the methylene chloride removed under reduced pressure.55.0 g (0.280 mol) of an oil was obtained as a compound of the formula III.
Reference: [1] Journal of Agricultural and Food Chemistry, 2012, vol. 60, # 35, p. 8544 - 8551
[2] Canadian Journal of Chemistry, 2007, vol. 85, # 2, p. 85 - 95
[3] Synthetic Communications, 2009, vol. 39, # 3, p. 395 - 406
[4] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 23, p. 7418 - 7429
[5] European Journal of Medicinal Chemistry, 2014, vol. 75, p. 111 - 122
[6] Tetrahedron, 2009, vol. 65, # 46, p. 9536 - 9541
[7] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 23, p. 5257 - 5261
[8] Journal of Medicinal Chemistry, 2009, vol. 52, # 21, p. 6672 - 6684
[9] Tetrahedron, 2010, vol. 66, # 34, p. 6718 - 6724
[10] Journal of Medicinal Chemistry, 2011, vol. 54, # 10, p. 3524 - 3548
[11] Letters in Organic Chemistry, 2013, vol. 10, # 3, p. 159 - 163
[12] Patent: WO2014/20462, 2014, A1, . Location in patent: Page/Page column 9
[13] Patent: CN107033054, 2017, A, . Location in patent: Paragraph 0070; 0071; 0075; 0076-0082; 0111; 0115-0118
  • 19
  • [ 79-37-8 ]
  • [ 35150-07-3 ]
  • [ 228244-04-0 ]
YieldReaction ConditionsOperation in experiment
66% With pyridine In ethyl acetate; N,N-dimethyl-formamide; acetonitrile Preparation 116
tert-butyl (2S)-2-cyano-1-pyrrolidinecarboxylate
A solution of oxalyl chloride (11.0 ml, 0.126 mol) and DMF (11.4 ml, 0.138 mol) in MeCN (170 ml) was treated dropwise with a solution of N-Boc-L-proline amide (12.3 g, 0.57mol) and pyridine (20.4 ml, 0.253 mol) in MeCN (30 ml) at 0° C. and stirred at this temperature for 15 minutes.
The reaction mixture was diluted with EtOAc and washed with H2O (*3).
The organic extract was dried over anhydrous MgSO4 and filtered.
The solvent was removed under reduced pressure.
The residue was purified on a silica column eluding with a solvent gradient of pentane:EtOAc (80:20) gradually changing to (60:40) to afford the title compound (7.40 g, 66percent).
1H nmr: (d6DMSO) 1.40 (9H, s), 1.88 (2H, brs), 2.05-2.30 (2H, m), 3.21 (1H, m), 3.35 (1H, brs), 4.60 (1H, d).
MS: 214 (MNH4+)
Reference: [1] Patent: US2002/151535, 2002, A1,
  • 20
  • [ 108-77-0 ]
  • [ 35150-07-3 ]
  • [ 228244-04-0 ]
YieldReaction ConditionsOperation in experiment
71% at 0℃; for 1 h; [0530] (S)-tert-butyl 2-cyanopyrrolidine-1-carboxylate (71b): To a solution of (S)-tert-butyl 2- carbamoylpyrrolidine-1-carboxylate 71a (86 mg, 0.40 mmol) in DME (2 mL) at 0 °C, 2,4,6-trichloro-1,3,5- triazine (104 mg, 0.56 mmol) was added. After stirring for one hour at 0°C, the reaction mixture was quenched with a cold 0.5 M NaOH solution. The mixture was then extracted with ethyl acetate. Organic layers were combined and washed with water and brine twice, dried over Na2SO4, and concentrated via vacuum. The crude reside was purified by silica gel column chromatography (15percent ethyl acetate hexane to yield 71b (56 mg, 71percent) as an oil. 1H NMR (500 MHz, CDCI3) 6 4.56-4.39 (m, 1H), 3.58-3.22 (m, 2H),2.28-1.94 (m, 4H), 1.47 (d, i=16.4 Hz, 9H); 13C NMR (126 MHz, CDCI3) 6 153.09, 119.23, 81.50, 47.27,45.79, 31.74, 28.39, 23.89; HRMS (ESI+): Calcd for C10H17N2O2 [M+H]: 197.1290, Found: 197.1287.
Reference: [1] Patent: WO2013/119946, 2013, A1, . Location in patent: Paragraph 0530
  • 21
  • [ 35150-07-3 ]
  • [ 207557-35-5 ]
Reference: [1] Patent: WO2014/20462, 2014, A1,
Recommend Products
Same Skeleton Products

Technical Information

• Acyl Group Substitution • Alcohols Convert Acyl Chlorides into Esters • Alcoholysis of Anhydrides • Amide Hydrolysis • Amide Hydrolysis • Amides Can Be Converted into Aldehydes • Amines Convert Acyl Chlorides into Amides • Amines Convert Esters into Amides • Bouveault-Blanc Reduction • Catalytic Hydrogenation • Chan-Lam Coupling Reaction • Claisen Condensations Produce β-Dicarbonyl Compounds • Claisen Condensations Produce β-Dicarbonyl Compounds • Complex Metal Hydride Reductions • Convert Esters into Aldehydes Using a Milder Reducing Agent • Decarboxylation of 3-Ketoacids Yields Ketones • Deprotection of Cbz-Amino Acids • Ester Cleavage • Ester Hydrolysis • Formation of an Amide from an Amine and a Carboxylic Acid • Formation of an Amide from an Amine and a Carboxylic Acid • Grignard Reagents Transform Esters into Alcohols • Hantzsch Pyridine Synthesis • Hofmann Rearrangement • Hydride Reductions • Ketones Undergo Mixed Claisen Reactions to Form β-Dicarbonyl Compounds • Lawesson's Reagent • Preparation of Amines • Reactions of Amines • Reactions with Organometallic Reagents • Reduction of an Amide to an Amine • Reduction of an Amide to an Amine • Reduction of an Ester to an Alcohol • Reduction of an Ester to an Aldehyde • Specialized Acylation Reagents-Carbodiimides and Related Reagents • Specialized Acylation Reagents-Ketenes • The Cycloaddition of Dienes to Alkenes Gives Cyclohexenes • Transesterification
Historical Records

Related Functional Groups of
[ 35150-07-3 ]

Amino Acid Derivatives

Chemical Structure| 109384-24-9

[ 109384-24-9 ]

(2S,4R)-tert-Butyl 2-carbamoyl-4-hydroxypyrrolidine-1-carboxylate

Similarity: 0.91

Chemical Structure| 73365-02-3

[ 73365-02-3 ]

N-Boc-D-Prolinal

Similarity: 0.90

Chemical Structure| 69610-41-9

[ 69610-41-9 ]

(S)-1-Boc-2-Formylpyrrolidine

Similarity: 0.90

Chemical Structure| 35150-08-4

[ 35150-08-4 ]

(S)-tert-Butyl (1-amino-3-methyl-1-oxobutan-2-yl)carbamate

Similarity: 0.85

Chemical Structure| 132622-66-3

[ 132622-66-3 ]

(2S,4S)-4-Amino-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid

Similarity: 0.83

; ;